Illumina Ventures overview
Stories about Illumina Ventures
Illumina Ventures aims to make a difference
A healthcare investor in the San Francisco Bay Area has its eyes on investments in cutting-edge genomics. The firm says its focus is rewarding and meaningful.
Stilla Technologies attracts $18 mln Series A
Stilla Technologies, a European provider of digital PCR solutions for high precision genetic analysis, has closed $18 million in Series A financing. Illumina Ventures led the round with participation from Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds and Idinvest Partners. In addition to the financing, Nick Naclerio of Illumina Ventures, Philippe Peltier of Kurma Partners and Philippe Chambon of LBO France have joined Stilla's board of directors.
Cernostics lands $2.5 mln
Pennsylvania-based Cernostics, a provider of next-generation cancer diagnostics and prognostics, has raised $2.5 million in Series A1 financing. Illumina Ventures led the round.
Illumina Ventures collects $230 mln for maiden fund
San Francisco-based Illumina Ventures, an early-stage venture firm, has raised $230 million for its debut fund. Illumina invests in early-stage companies focused on genomics and precision medicine.
Illumina Ventures contact information
Offices
500 Lincoln Centre Drive, Suite 110, Foster City, 94404, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Dr. Charles Lin | Job titlePrincipal, Investments | LocationFoster City, United States | Email  --------- |
| Mr. Donal Delaney | Job titleChief Financial Officer | LocationFoster City, United States | Email ---------- |
| Dr. Abhijit “Ron” Mazumder | Job titlePartner | LocationFoster City, United States | Email --------- |
| Ms. Mara Aspinall | Job titlePartner | LocationFoster City, United States | Email ------ |
Illumina Ventures funds managed
Funds in market: 1
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size -------- | Open dateAug 2024 | Strategy ------ | |
Closed funds: 2
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ---------- | Close dateJun 2021 | Strategy ---------- | |
Fund size ------ | Close dateOct 2017 | Strategy ------ | |
Stories that mention Illumina Ventures
Sherlock Biosciences fetches $80m Series B
Sherlock Biosciences, a next-generation diagnostics company, has raised $80 million in Series B financing.
Walking Fish Therapeutics picks up $50m Series A
Walking Fish Therapeutics, a B cell engineering company, has raised $50 million in Series A financing.
Virtual care firm LetsGetChecked nets $150m Series D
LetsGetChecked, a virtual care company, has secured $150 million in Series D financing.
VC-backed SQZ Biotech goes public
Watertown, Massachusetts-based SQZ Biotechnologies Company, a cell therapy company, has debuted its IPO after pricing its over 4.4 million shares at $16 per share.
VC-backed Ribometrix appoints Phillips as COO and CFO
Durham, North Carolina-based Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, has named Barclay Phillips as chief operating officer and chief financial officer.
Encoded Therapeutics scores $135m Series D
South San Francisco-based Encoded Therapeutics, a precision gene therapy company, has raised $135 million in Series D financing.
Pattern Bioscience attracts $9m
Austin-based Pattern Bioscience, an in vitro diagnostics company, has raised $9 million in funding.
SQZ Biotech grabs $65m
Watertown, Massachusetts-based SQZ Biotechnologies Company, a cell therapy company, has raised $65 million in Series D preferred stock financing.